Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Nicholas P. Restifo, Mark E. Dudley, Susan L. Schwarz, Paul J. Spiess, John R. Wunderlich, Maria R. Parkhurst, Yutaka Kawakami, Claudia A. Seipp, Jan H. Einhorn, Donald E. White

研究成果: Article査読

1686 被引用数 (Scopus)

抄録

The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

本文言語English
ページ(範囲)321-327
ページ数7
ジャーナルNature medicine
4
3
DOI
出版ステータスPublished - 1998
外部発表はい

ASJC Scopus subject areas

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル